Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA for Photodynamic Diagnosis of Malignant Brain Glioma
NCT06417281Phase 3Completed
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 5-aminolevulinic acid in malignant glioma, sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoint: Positive Predictive Rate at 48 hours. Started Jun 2024; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT06417281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06417281.